Re: Farmas USA
ARRY
Phase 3 COLUMBUS trial NDA of binimetinib, in combination with encorafenib, for the treatment of BRAF-mutant melanoma, which remains on track for mid-2017.
NDA submission of binimetinib, in combination with encorafenib, for BRAF-mutant melanoma expected in mid-2017
OMER
Esto es de octubre, no sé si se ha producido o no
the company is also pursuing breakthrough therapy designation for OMS721 in IgA nephropathy and in HSCT-TMAs, neither of which has any approved treatment
«Después de nada, o después de todo/ supe que todo no era más que nada.»